Three lipid formulations of amphotericin B are now either marketed for clinical use or undergoing further study before they can be approved in various countries worldwide. Amphotericin B lipid complex (ABLC; Abelcet, Liposome Company, Princeton, NJ) is a concentration of ribbonlike structures of a bilayered membrane formed by combining a 7:3 molar ratio of dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol with amphotericin B. Amphotericin B colloidal dispersion (ABCD; Amphocil, Sequus Pharmaceuticals, Menlo Park, CA) is composed of disklike structures of cholesteryl sulfate complexed with amphotericin B. AmBisome (Nexstar, San Dimas, CA), the only true liposomal amphotericin B, consists of small unilamellar vesicles made up of a bilayer membrane of hydrogenated soy phosphatidylcholine and distearoylphosphatidylglycerol stabilized with cholesterol in a 2:0.8:1 ratio combined with amphotericin B. All of the preparations appear to be preferentially accumulated in organs of the reticuloendothelial system, as opposed to the kidney. In vivo animal models as well as current clinical experience suggest that use of these formulations results in overall improvement in the therapeutic index. Patients with life-threatening mycosis for whom therapy has failed or who are intolerant to therapy with amphotericin B deoxycholate have been successfully treated with these formulations. However, further study is warranted to help clarify the usefulness of each of the lipid formulations as first-line therapy for documented or suspected invasive fungal infections.
England, was the first to demonstrate that, at high concentrations, phospholipids dispersed in water spontaneously form microscopic closed vesicles. These vesicles consisted of water surrounded by bilayered phospholipid membranes. Bangham called these tiny fat bubbles "smectic mesophases." They were later named "liposomes" by his colleague Gerald Weissman [20, 21] . Liposomes are composed of biodegradable phospholipid molecules that are made up of a hydrophilic head attached to a hydrophobic tail. When placed in water, the molecules spontaneously arrange themselves into bilayered membranes, which coalesce to form vesicles. The hydrophilic heads face outward, shielding the hydrophobic tails. Spherical vesicles form to protect the hydrophobic ends (figure 1). Since Bangham's description of liposomes over 30 years ago, numerous methods of creating these molecules have been outlined in several publications. Biochemists, biophysicists, and physiologists have been able to alter the size, charge, permeability, and even number of bilayered membranes in a liposome. Physiologists have used liposomes in the study of cell membrane interactions.
Numerous studies over the last two decades have investigated the practical use of liposomes. Water-soluble substances such as drugs, enzymes, and even genes have been entrapped in the aqueous phase of the bilayer. Fat-soluble substances such as polyene antibiotics can be incorporated into the lipid bilayer.
The pharmacokinetics and pharmacodynamics of drugs incorporated into liposomes may differ greatly from those of the free counterpart. This new drug-delivery system may help to better target certain pharmaceuticals, thus improving their therapeutic index [21] . Studies suggest that drugs incorporated into liposomes or lipid formulations are selectively taken up into the reticuloendothelial system and concentrated in the liver, spleen, lungs, lymph nodes, and, to a lesser extent, bone marrow. Lipid-rich particles are also believed to be ingested by phagocytic cell monocytes, which may help to target sites of infection or inflammation [20, 21] .
Liposomal Amphotericin B
Amphotericin B, which is highly lipophilic, was first incorporated into liposomes over 10 years ago in an attempt to increase its therapeutic index. In 1981, New . Liposomes created by Lopez-Berestein and Juliano were multilamellar vesicles consisting of a mixture of the two phospholipids dimyristoyl phosphatidylcholine (DMPC) and dimyristoyl phosphatidylglycerol (DMPG) in a 7:3 molar ratio containing 5%-10% mole ratio of amphotericin to lipid. Preliminary compassionateuse experience with this product in severely immunocompromised cancer patients with progressive fungal infections at the M. D. Anderson Hospital and Tumor Institute (Houston) suggested that invasive disease could be controlled even in patients for whom conventional amphotericin B therapy had previously failed. Moreover, the liposomal product had significantly less nephrotoxicity than conventional amphotericin B even at much higher doses [26, 27] .
This experience led to further development of lipid formulations of amphotericin B by the pharmaceutical industry over the last decade. There are three products that currently are undergoing clinical trials in the United States. All three have been licensed for clinical use and are currently available commercially in a number of countries in Westem Europe. One lipid formulation of amphotericin B, amphotericin B lipid complex (ABLC; Abelcet Liposome Company, Princeton, NJ) has recently been approved by the U.S. Food and Drug Administra- 
Amphotericin B Lipid Complex
In attempting to explain why the product developed by Berestein and Juliano could be significantly less toxic than conventional amphotericin B while maintaining its efficacy, Janoff and colleagues began a series of experiments to study this form of lipid-associated amphotericin B in their laboratory located in Princeton, New Jersey. They found that the original formulation of lipid-associated amphotericin B contained a variety of liposomal and nonliposomal structures of lipid bilayers. It appeared that the nonliposomal structures in the formation that they called "ribbons" were responsible for the reduction in toxicity [28, 29] . They subsequently performed a series of experiments combining the lipid formulation of DMPC and DMPG in a 7:3 molar ratio with varying concentrations of amphotericin B.
Freeze-etch electron microscopy of formulations made with 0, 5, 25, and 50 mol% of amphotericin B showed significant differences in the structures formed. The formulation made up of 5%mole concentration of amphotericin B, which was similar to the Berestein/Juliano product, consisted of lipid vesicles smaller than the large vesicles that formed in the absence of amphotericin B. It also contained the ribbonlike structures seen in the original product. When the concentration of amphotericin B was increased to 25 mol%, "liposomal" vesicles essentially disappeared and were replaced by tightly packed ribbon structures. At concentrations of >50 mol% amphotericin B, the formulation continued to appear as ribbon structures; however, the amphotericin B and lipid were no longer closely complexed (figures 3 and 4). The ribbon structures formed by complexing DMPC and DMPG with amphotericin B were called "amphotericin B lipid complex" or "ABLC."
In vitro studies suggested that the hemolytic activity of this lipid formulation at low concentrations (<3 mol% of amphotericin B to lipid) was similar to that of conventional amphotericin B, but as the mole ratio of amphotericin B increased and the ribbon structures began to form, there was a marked reduction of overall toxicity. As amphotericin B is increasingly complexed with the lipid, the amount of free amphotericin B in solution is reduced, presumably accounting for the decreased toxicity. The efficacy of ABLC has also been attributed to the ability of lipases from either fungi or inflammatory cells at the site of infection to release the complexed amphotericin B from the lipid formulation. However, the improvement in the therapeutic index may also be related to binding to high density lipoproteins as well as to selective interaction with fungal cell membranes [30] .
Animal models. ABLC has been compared with conventional amphotericin B in a number of animal models including mice, rats, rabbits, and dogs. Concentrations of amphotericin B in the liver, spleen, and lungs of mice and rats appear to be much higher after a single dose of ABLC than after a single dose of amphotericin B deoxycholate. The level of amphotericin B found in the kidney tissue of mice appeared similar to the level of amphotericin B after injection of ABLC at the 1 mg/kg dose. However, plasma levels of amphotericin B were consistently lower after injection of the lipid complex ABLC than were levels obtained after injection of amphotericin B deoxycholate. When increasing the dose of the lipid complex, the levels of drug in the liver, spleen, and lung tissue rise dramatically; however, this rise is associated with little change in the levels of drug in the kidney and essentially no rise in plasma levels [29, 31, 32] . Studies in mice showed that after a single iv dose the LD50 for the lipid complex of amphotericin B was 40 mg/kg whereas that for conventional amphotericin B was 3 mg/ kg. Multiple-dose studies of ABLC continued to show a significant reduction in toxicity even at 10 times the standard ._- dose of conventional amphotericin B in mice [31] and four times the standard dose in rabbits [33] .
The efficacy of ABLC has also been evaluated in a number of animal models of fungal infection and was found to be comparable to that of conventional amphotericin B. Moreover, in a number of cases the lipid formulation was effective when conventional amphotericin B was ineffective at controlling the fungal infection at the maximum tolerated dose [31, 34, 35] . ABLC (10 mg/kg) also demonstrated rapid fungicidal activity in the treatment of experimental cryptococcal meningitis [36] . The ability to deliver much higher doses of amphotericin B in the form of a lipid complex without reaching the maximum tolerated dose was thought to account for the improved therapeutic index [29] .
Human studies. The pharmacokinetics of ABLC in humans resembles those in animals. Circulating blood levels of ampho-tericin B were much lower in male volunteers after singledose infusion of ABLC than after infusion of conventional amphotericin B deoxycholate [37] . The lipid complex is believed to be rapidly taken up by the reticuloendothelial system and concentrated in the liver, spleen, lungs, and other tissues of the body. Tissue levels of amphotericin B were measured at autopsy of a heart transplant patient after 3 days of treatment with ABLC. Relatively high concentrations of amphotericin B were detected in the spleen (290 /ug/g), liver (196 /tg/g), and lungs (222 ,ug/g). Lower concentrations were detected in the kidney (6.9 ,g/g), lymph nodes (7.6 /ug/g), brain (1.6 /tg/g), and heart (4.9 /ug/g) (J. A. Boyle, unpublished data). ABLC was administered for a median duration of 25 days at a mean maximum dose of 5 mg/(kg. d). Clinical response rates, as assessed by the patient's primary physician, were 78% (52/67) for candidiasis and 60% (43/72) for aspergillosis. Use of ABLC was associated with a decrease in the serum creatinine level during therapy. The mean serum creatinine level declined significantly (P = .0001) from baseline in the entire population and in the subgroup whose initial serum creatinine level was >2.5 mg/dL (n = 62). ABLC was effective in patients with invasive mycoses who were unresponsive to or intolerant of previous antifungal therapy and was infrequently associated with dose-limiting nephrotoxicity [42] .
ABLC has been compared with conventional amphotericin B in a number of small phase II and phase III clinical trials of patients with leishmaniasis, coccidioidomycosis, and cryptococcosis. A dose-escalation trial of ABLC vs. conventional
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Therapy with amphotericin B deoxycholate is frequently started empirically long before invasive aspergillosis is documented, making it difficult to compare the lipid formulation to its parent drug in a prospective randomized trial. Data from 151 patients with definite or probable invasive aspergillosis who had been treated with ABLC according to emergency-use protocols were therefore compared to data from medical charts of 122 control patients with aspergillosis who had been treated with conventional amphotericin B. Patients treated with ABLC showed higher overall response rates (40% vs. 23%; P = .002) than patients who were treated with amphotericin B. Moreover, patients whose serum creatinine level was 5>2.5 mg/dL at the initiation of treatment with ABLC had a significant decrease in their serum creatinine levels between weeks 2 and 5 (P < .004) despite continued therapy with 5 mg/(kg * d) of this drug. Although trials with historical controls have major limitations, ABLC appeared to be less nephrotoxic and at least as effective for treating invasive aspergillosis, even in cases where therapy with at least 500 mg of amphotericin B deoxycholate had failed to control infection [43] . Animal models of systemic coccidioidomycosis, cryptococcosis, and aspergillosis have been used to study the relative efficacy of ABCD compared with amphotericin B deoxycholate [49] [50] [51] [52] [53] . Although the doses of amphotericin B deoxycholate (1.3 mg/kg) required to clear the organs of fungi in a mouse model of coccidioidomycosis were lower than those required for ABCD (5 mg/kg), the lipid formulation had a significantly better therapeutic index, as amphotericin B deoxycholate was found to be 5-8 times more toxic than ABCD [49] . Unlike the murine model of coccidioidomycosis, a murine model of cryptococcosis showed that ABCD had equal efficacy when it was compared with amphotericin B on a mg/kg basis. ABCD was again found to be less toxic, suggesting an improvement in the therapeutic index for the lipid formulation [50] .
Rabbit models of invasive aspergillosis suggest that amphotericin B deoxycholate is superior to ABCD in tissue clearance of fungi at equal doses of 1 mg/kg [51, 52] . However, increased duration of survival was observed in persistently granulocytopenic rabbits with pulmonary aspergillosis when 5 mg/(kg-d) of ABCD were compared with 1 mg/(kg. d) of amphotericin B deoxycholate [52] . The investigators attributed the improved therapeutic index to an enhanced rate of tissue clearance, decreased pulmonary injury, and reduced nephrotoxicity in the rabbits treated with 5 mg/(kg * d) of ABCD. These findings were further confirmed in a study of the evolution of pulmonary infiltrates in experimental pulmonary aspergillosis. 
With use of ultrafast CT scanning and an image-analysis algorithm, a dose-dependent clearance of pulmonary infiltrates in rabbits treated with ABCD was documented [53]. Higher doses of ABCD (5 and 10 mg/[kg -d]) exerted a rapid clearing effect on the development of pulmonary lesions in comparison with the response rates of amphotericin B at 1 mg/(kg d). Human studies. Hostetler et al. studied relatively low doses of ABCD (up to 1 mg/[kg. d] or 2 mg/kg three times weekly up to 10 weeks) for a group of patients with coccidioidomycosis whose therapy had failed or who were intolerant to prior antifungal therapy. Although fever and rigors were common (75% and 83% of patients, respectively), adverse events rarely limited therapy. Most patients (71%) had at least a minor response to ABCD therapy, and a few (13%) had a major response with use of the clinical scoring system adapted for coccidioidomycosis [54]. A preliminary report by Bowden and Cays of a phase 1 clinical trial of ABCD suggested that doses of up to 7 mg/ (kg * d) may be well tolerated and effective in the setting of opportunistic fungal infection [55]. The results of an open-labeled compassionate-use trial of 168 patients with documented or presumed invasive mycosis who were treated with ABCD were recently reported. Patients were eligible for enrollment in the study if their fungal infection had failed to adequately respond to a minimum of 7 days of treatment with conventional amphotericin B deoxycholate or if they had renal insufficiency that was preexisting or secondary to acute drug-related nephrotoxicity (usually due to therapy with conventional amphotericin B deoxycholate).
The initial dose of ABCD was variable (0.5, 1, 2, 3, or 4 mg/ [kg d]) and was dependent on the individual investigator's judgement. A daily dose of 3 mg/(kg d) was recommended for candidiasis and other yeastlike fungi, whereas 4 mg/ (kg. d) was recommended for infections due to
. The in vitro antifungal activity of AmBisome was found to be comparable to that of amphotericin B when a number of clinical isolates from a large cancer center were tested [58]. A recent report, however, suggested that the small unilamellar liposomal form of amphotericin B may be as much as 4-8 times less active than the deoxycholate form against several isolates of C. albicans [59]. It is unclear what the significance of in vitro susceptibility testing is for lipid formulations of amphotericin B. Unlike in vitro antibacterial drug susceptibility testing, in vitro antifungal drug susceptibility tests have been hard to duplicate from laboratory to laboratory. Moreover, lipid formulations of amphotericin B were specifically designed to complex or bind the antifungal for targeted drug delivery.
There may be a need for the drug to be taken up by the reticuloendothelial system or to be delivered to points of infection to realize a therapeutic advantage.
Animal models. The pharmacokinetics, toxicity, and efficacy of AmBisome have been studied in the mouse, rat, and rabbit [60, 61] . Peak plasma levels that can be obtained with the liposomal form of amphotericin B were similar in mice, rats, and rabbits. Liposomal amphotericin B is similar to the other lipid formulations of amphotericin B as it appears to be preferentially concentrated in the liver and spleen of animals; however, the rate of uptake by the reticuloendothelial system appears to be much slower than that by ABLC or ABCD. It is hypothesized that the larger lipid complexes and dispersions may be more readily phagocytized by the macrophages of the reticuloendothelial system than the smaller unilamellar vesicles. The negative charge on the AmBisome particle also may delay uptake by the reticuloendothelial system. These mechanisms may account for the fact that the liposomal form of amphotericin B has much higher peak plasma levels and a prolonged circulation time compared with its larger counterparts.
AmBisome has been found to be less nephrotoxic than conventional amphotericin B in the mouse, rat, and rabbit models. 
Future Directions for Research
Lipid formulations of amphotericin B have been undergoing clinical investigation for over a decade. Many questions, however, remain to be elucidated. For example, little is known about the comparative efficacy and pharmacodynamics of these compounds. More work is clearly required in clarifying their mechanism of action, the basis of the improved therapeutic index, and the selective cytotoxicity. Drug interactions as well as the possibility of any long-term toxic effects need to be studied, particularly in patients who receive many months of therapy for chronic invasive mycosis. An understanding of the interaction of lipid formulations of amphotericin B with immunomodulators such as cytokines and interleukins is also necessary, when the use of such combinations is considered. Further definition of the clinical usefulness of the lipid formulations of amphotericin B in specific target populations (e.g., newbom infants, children, diabetics, organ transplant recipients, surgical intensive care patients, HIV-infected patients, and neutropenic patients) and for specific fungal infections is needed. Only through the use of thoughtfully designed, carefully conducted, well-controlled clinical trials will we increase our understanding of the appropriate use of these compounds (table 2 
